Drug Profile
Mitoxantrone
Alternative Names: CL 232315; DHAD; DHAQ; dihydroxyanthracenedione; mitozantrone; Novantron; Novantrone; NSC 279836; NSC 301739; Onkotrone; PralifanLatest Information Update: 30 Jun 2023
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Amgen; Pfizer; Takeda
- Class Anthraquinones; Antineoplastics; Small molecules
- Mechanism of Action DNA inhibitors; DNA topoisomerase inhibitors; Immunosuppressants; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute myeloid leukaemia; Acute nonlymphocytic leukaemia; Acute promyelocytic leukaemia; Breast cancer; Cancer; Cancer pain; Leukaemia; Liver cancer; Multiple sclerosis; Non-Hodgkin's lymphoma; Ovarian cancer
Most Recent Events
- 12 May 2023 University of Washington in collaboration with AbbVie suspends phase I trial in phase I trial for acute myeloid leukaemia (Combination therapy, Second-line or greater therapy) in USA due to pending protocol amendment (IV) (NCT04797767)
- 29 Nov 2021 University of Washington in collaboration with AbbVie initiates enrolment in a phase I trial for acute myeloid leukaemia (Combination therapy, Second-line or greater therapy) in USA (IV) (NCT04797767)
- 09 Jun 2010 OSI Pharmaceuticals has been acquired by Astellas Pharma